Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tomography, X-Ray Computed | 220 | 2024 | 2436 | 21.120 |
Why?
|
Friedreich Ataxia | 57 | 2023 | 64 | 19.700 |
Why?
|
Lung Diseases, Interstitial | 78 | 2024 | 464 | 12.400 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 89 | 2023 | 1137 | 10.720 |
Why?
|
Pulmonary Emphysema | 62 | 2024 | 327 | 10.260 |
Why?
|
Idiopathic Pulmonary Fibrosis | 53 | 2024 | 451 | 8.610 |
Why?
|
Lung | 127 | 2024 | 3664 | 6.570 |
Why?
|
Iron-Binding Proteins | 29 | 2023 | 38 | 5.010 |
Why?
|
Lung Diseases | 29 | 2023 | 718 | 4.470 |
Why?
|
Pulmonary Fibrosis | 26 | 2023 | 303 | 4.060 |
Why?
|
Smoking | 56 | 2023 | 1487 | 3.810 |
Why?
|
Emphysema | 15 | 2024 | 123 | 3.720 |
Why?
|
Humans | 403 | 2024 | 118974 | 2.870 |
Why?
|
Radiography, Thoracic | 22 | 2018 | 164 | 2.750 |
Why?
|
Lung Neoplasms | 28 | 2023 | 2220 | 2.640 |
Why?
|
Alveolitis, Extrinsic Allergic | 13 | 2023 | 83 | 2.600 |
Why?
|
Idiopathic Interstitial Pneumonias | 14 | 2019 | 41 | 2.510 |
Why?
|
Middle Aged | 186 | 2024 | 27617 | 2.380 |
Why?
|
Smokers | 16 | 2023 | 149 | 2.380 |
Why?
|
Aged | 149 | 2022 | 19657 | 2.090 |
Why?
|
Diagnostic Imaging | 9 | 2022 | 294 | 2.080 |
Why?
|
Male | 223 | 2024 | 57801 | 2.000 |
Why?
|
Severity of Illness Index | 48 | 2023 | 2674 | 2.000 |
Why?
|
Pattern Recognition, Automated | 4 | 2018 | 76 | 1.950 |
Why?
|
Disease Progression | 47 | 2023 | 2490 | 1.940 |
Why?
|
Biopsy | 27 | 2023 | 1079 | 1.900 |
Why?
|
Trinucleotide Repeat Expansion | 12 | 2023 | 26 | 1.880 |
Why?
|
Female | 220 | 2024 | 61565 | 1.880 |
Why?
|
Forced Expiratory Volume | 36 | 2023 | 520 | 1.870 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 9 | 2021 | 191 | 1.860 |
Why?
|
Diagnosis, Differential | 39 | 2023 | 1384 | 1.630 |
Why?
|
Mucin-5B | 10 | 2020 | 175 | 1.560 |
Why?
|
Quality of Life | 22 | 2024 | 2366 | 1.500 |
Why?
|
Connective Tissue Diseases | 9 | 2019 | 57 | 1.480 |
Why?
|
Bronchiectasis | 10 | 2024 | 105 | 1.420 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 11 | 2017 | 109 | 1.420 |
Why?
|
Respiratory Function Tests | 27 | 2021 | 526 | 1.410 |
Why?
|
Vital Capacity | 24 | 2024 | 260 | 1.390 |
Why?
|
Incidental Findings | 3 | 2021 | 80 | 1.370 |
Why?
|
Reproducibility of Results | 38 | 2024 | 2874 | 1.360 |
Why?
|
Cohort Studies | 40 | 2023 | 5116 | 1.290 |
Why?
|
Magnetic Resonance Imaging | 18 | 2023 | 3174 | 1.280 |
Why?
|
Image Processing, Computer-Assisted | 10 | 2019 | 709 | 1.260 |
Why?
|
Aged, 80 and over | 49 | 2021 | 6561 | 1.250 |
Why?
|
Early Detection of Cancer | 9 | 2023 | 360 | 1.220 |
Why?
|
Adult | 95 | 2024 | 31512 | 1.220 |
Why?
|
Occupational Diseases | 5 | 2015 | 136 | 1.150 |
Why?
|
Pulmonary Artery | 6 | 2021 | 1063 | 1.150 |
Why?
|
Vision Disorders | 2 | 2020 | 135 | 1.090 |
Why?
|
Respiratory System Abnormalities | 2 | 2022 | 11 | 1.090 |
Why?
|
Spirometry | 24 | 2023 | 263 | 1.030 |
Why?
|
Schizophrenia | 4 | 2022 | 501 | 1.010 |
Why?
|
Common Variable Immunodeficiency | 3 | 2018 | 27 | 1.010 |
Why?
|
Sarcoidosis | 2 | 2018 | 130 | 1.000 |
Why?
|
Sensitivity and Specificity | 24 | 2021 | 1795 | 0.970 |
Why?
|
Positron-Emission Tomography | 5 | 2018 | 298 | 0.960 |
Why?
|
Lymph Nodes | 2 | 2019 | 455 | 0.960 |
Why?
|
Retrospective Studies | 50 | 2024 | 12978 | 0.950 |
Why?
|
Trinucleotide Repeats | 5 | 2023 | 24 | 0.950 |
Why?
|
Lung Injury | 2 | 2024 | 210 | 0.930 |
Why?
|
Respiratory-Gated Imaging Techniques | 3 | 2017 | 8 | 0.920 |
Why?
|
Paranasal Sinuses | 2 | 2020 | 64 | 0.900 |
Why?
|
Triterpenes | 1 | 2023 | 17 | 0.900 |
Why?
|
Linoleic Acid | 1 | 2022 | 41 | 0.880 |
Why?
|
Anthracosis | 1 | 2022 | 3 | 0.860 |
Why?
|
Young Adult | 27 | 2021 | 10793 | 0.840 |
Why?
|
Pulmonary Diffusing Capacity | 10 | 2020 | 58 | 0.830 |
Why?
|
Sinusitis | 2 | 2022 | 175 | 0.810 |
Why?
|
Homeostasis | 2 | 2016 | 594 | 0.810 |
Why?
|
Multiple Pulmonary Nodules | 2 | 2019 | 26 | 0.810 |
Why?
|
Predictive Value of Tests | 12 | 2021 | 1868 | 0.790 |
Why?
|
Prognosis | 23 | 2024 | 3443 | 0.770 |
Why?
|
Neurodegenerative Diseases | 1 | 2022 | 99 | 0.760 |
Why?
|
Machine Learning | 9 | 2020 | 331 | 0.760 |
Why?
|
Visual Acuity | 2 | 2020 | 272 | 0.750 |
Why?
|
Ataxia | 3 | 2023 | 38 | 0.740 |
Why?
|
Case-Control Studies | 23 | 2020 | 3171 | 0.740 |
Why?
|
Longitudinal Studies | 17 | 2023 | 2513 | 0.720 |
Why?
|
Cystic Fibrosis | 6 | 2022 | 964 | 0.720 |
Why?
|
Dyspnea | 5 | 2023 | 201 | 0.720 |
Why?
|
Calcinosis | 1 | 2022 | 282 | 0.720 |
Why?
|
Double-Blind Method | 13 | 2023 | 1687 | 0.710 |
Why?
|
Cardiomyopathies | 3 | 2021 | 299 | 0.690 |
Why?
|
Adolescent | 32 | 2021 | 18480 | 0.690 |
Why?
|
Phenotype | 21 | 2023 | 3003 | 0.670 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2013 | 374 | 0.670 |
Why?
|
Antioxidants | 2 | 2014 | 564 | 0.660 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2021 | 454 | 0.640 |
Why?
|
Bronchitis, Chronic | 4 | 2023 | 20 | 0.640 |
Why?
|
Prospective Studies | 27 | 2024 | 6471 | 0.630 |
Why?
|
Algorithms | 10 | 2020 | 1541 | 0.630 |
Why?
|
Collagen Diseases | 3 | 2012 | 6 | 0.630 |
Why?
|
Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2017 | 13 | 0.630 |
Why?
|
Thoracic Diseases | 2 | 2015 | 13 | 0.620 |
Why?
|
Occupational Exposure | 7 | 2020 | 277 | 0.620 |
Why?
|
Neurons | 8 | 2018 | 1345 | 0.620 |
Why?
|
Risk Factors | 32 | 2021 | 9000 | 0.610 |
Why?
|
Genotype | 13 | 2020 | 1882 | 0.600 |
Why?
|
Calpain | 3 | 2007 | 54 | 0.590 |
Why?
|
Patient Satisfaction | 1 | 2021 | 610 | 0.590 |
Why?
|
Mental Health Services | 1 | 2021 | 331 | 0.590 |
Why?
|
Interdisciplinary Communication | 2 | 2016 | 191 | 0.590 |
Why?
|
Sarcoidosis, Pulmonary | 2 | 2016 | 56 | 0.580 |
Why?
|
Immunoassay | 3 | 2014 | 101 | 0.580 |
Why?
|
Interferon-gamma | 2 | 2019 | 736 | 0.580 |
Why?
|
Observer Variation | 11 | 2021 | 309 | 0.580 |
Why?
|
Bronchiolitis | 4 | 2015 | 83 | 0.570 |
Why?
|
Echocardiography | 4 | 2017 | 556 | 0.560 |
Why?
|
Biomarkers | 14 | 2023 | 3588 | 0.550 |
Why?
|
Mitochondria | 4 | 2020 | 786 | 0.550 |
Why?
|
Opsoclonus-Myoclonus Syndrome | 1 | 2015 | 1 | 0.540 |
Why?
|
Dendrites | 2 | 2018 | 88 | 0.540 |
Why?
|
Telemedicine | 2 | 2021 | 664 | 0.540 |
Why?
|
Antigens, Surface | 2 | 2015 | 156 | 0.540 |
Why?
|
Asthma | 7 | 2023 | 2158 | 0.540 |
Why?
|
Genetic Predisposition to Disease | 19 | 2020 | 2275 | 0.540 |
Why?
|
Mass Screening | 6 | 2023 | 1052 | 0.540 |
Why?
|
Genome-Wide Association Study | 12 | 2020 | 1323 | 0.530 |
Why?
|
Metabolic Diseases | 1 | 2016 | 103 | 0.520 |
Why?
|
Child | 30 | 2024 | 19129 | 0.520 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 687 | 0.520 |
Why?
|
Airway Remodeling | 7 | 2021 | 57 | 0.520 |
Why?
|
Mycobacterium avium-intracellulare Infection | 1 | 2016 | 62 | 0.510 |
Why?
|
Follow-Up Studies | 18 | 2023 | 4596 | 0.510 |
Why?
|
Pneumonia, Bacterial | 1 | 2016 | 110 | 0.500 |
Why?
|
Nerve Tissue Proteins | 6 | 2018 | 551 | 0.500 |
Why?
|
Lymphatic Diseases | 1 | 2014 | 18 | 0.490 |
Why?
|
Mouth Mucosa | 2 | 2014 | 82 | 0.480 |
Why?
|
Polymorphism, Single Nucleotide | 10 | 2018 | 2062 | 0.480 |
Why?
|
Radiographic Image Enhancement | 5 | 2020 | 65 | 0.480 |
Why?
|
Autoantibodies | 7 | 2015 | 1335 | 0.480 |
Why?
|
Arthritis, Rheumatoid | 6 | 2022 | 989 | 0.480 |
Why?
|
Heterozygote | 5 | 2020 | 262 | 0.480 |
Why?
|
Vascular Diseases | 2 | 2009 | 241 | 0.470 |
Why?
|
Regression Analysis | 11 | 2019 | 983 | 0.470 |
Why?
|
Support Vector Machine | 1 | 2013 | 36 | 0.460 |
Why?
|
Polymorphism, Genetic | 4 | 2017 | 642 | 0.460 |
Why?
|
Neuronal Plasticity | 3 | 2010 | 219 | 0.450 |
Why?
|
Tomography, Spiral Computed | 4 | 2013 | 24 | 0.450 |
Why?
|
Spinocerebellar Degenerations | 2 | 2023 | 5 | 0.450 |
Why?
|
Cerebellar Ataxia | 2 | 2023 | 7 | 0.450 |
Why?
|
Elasticity Imaging Techniques | 1 | 2013 | 44 | 0.440 |
Why?
|
Sequence Analysis, RNA | 5 | 2018 | 409 | 0.440 |
Why?
|
Receptor for Advanced Glycation End Products | 3 | 2022 | 34 | 0.440 |
Why?
|
United States | 32 | 2024 | 12555 | 0.440 |
Why?
|
Angiography | 2 | 2013 | 185 | 0.440 |
Why?
|
Cells, Cultured | 10 | 2021 | 4077 | 0.430 |
Why?
|
Exhalation | 3 | 2018 | 35 | 0.430 |
Why?
|
Heart Diseases | 2 | 2017 | 341 | 0.430 |
Why?
|
Receptors, Nicotinic | 3 | 2015 | 295 | 0.430 |
Why?
|
NF-E2-Related Factor 2 | 2 | 2023 | 83 | 0.420 |
Why?
|
Vena Cava, Superior | 1 | 2012 | 21 | 0.420 |
Why?
|
Point Mutation | 4 | 2014 | 228 | 0.410 |
Why?
|
Asymptomatic Diseases | 1 | 2012 | 81 | 0.410 |
Why?
|
Risk Assessment | 8 | 2019 | 3057 | 0.410 |
Why?
|
Osteosarcoma | 1 | 2012 | 71 | 0.410 |
Why?
|
Troponin I | 1 | 2012 | 83 | 0.410 |
Why?
|
Pandemics | 5 | 2024 | 1355 | 0.410 |
Why?
|
Comorbidity | 9 | 2018 | 1527 | 0.400 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 4 | 2022 | 288 | 0.400 |
Why?
|
Echocardiography, Doppler | 1 | 2011 | 95 | 0.400 |
Why?
|
Health Status | 5 | 2014 | 726 | 0.400 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2011 | 107 | 0.390 |
Why?
|
Glucose | 1 | 2016 | 953 | 0.390 |
Why?
|
Genetic Variation | 4 | 2019 | 926 | 0.390 |
Why?
|
Imaging, Three-Dimensional | 5 | 2021 | 499 | 0.390 |
Why?
|
Respiratory Tract Diseases | 3 | 2018 | 143 | 0.390 |
Why?
|
Doxorubicin | 1 | 2012 | 302 | 0.390 |
Why?
|
Heart Transplantation | 1 | 2017 | 671 | 0.380 |
Why?
|
Pulmonary Embolism | 2 | 2012 | 183 | 0.380 |
Why?
|
Ubiquinone | 1 | 2010 | 25 | 0.380 |
Why?
|
Mutation | 7 | 2022 | 3457 | 0.380 |
Why?
|
Mass Spectrometry | 6 | 2023 | 681 | 0.380 |
Why?
|
Databases, Factual | 2 | 2015 | 1231 | 0.370 |
Why?
|
Cysts | 3 | 2023 | 93 | 0.370 |
Why?
|
Dysarthria | 1 | 2010 | 9 | 0.370 |
Why?
|
Presynaptic Terminals | 1 | 2010 | 58 | 0.370 |
Why?
|
Stroke Volume | 2 | 2017 | 513 | 0.370 |
Why?
|
Bone Neoplasms | 1 | 2012 | 199 | 0.360 |
Why?
|
Image Interpretation, Computer-Assisted | 4 | 2020 | 220 | 0.360 |
Why?
|
Myocardial Contraction | 1 | 2011 | 339 | 0.360 |
Why?
|
Survival Analysis | 7 | 2020 | 1267 | 0.360 |
Why?
|
Radiation Dosage | 5 | 2022 | 147 | 0.360 |
Why?
|
Pulmonary Atelectasis | 3 | 2018 | 13 | 0.360 |
Why?
|
Encephalitis | 2 | 2008 | 129 | 0.360 |
Why?
|
Hyperostosis, Diffuse Idiopathic Skeletal | 2 | 2019 | 4 | 0.350 |
Why?
|
Multivariate Analysis | 10 | 2019 | 1474 | 0.350 |
Why?
|
Bronchi | 2 | 2024 | 242 | 0.340 |
Why?
|
Surveys and Questionnaires | 11 | 2021 | 4708 | 0.340 |
Why?
|
Gadolinium | 4 | 2020 | 79 | 0.340 |
Why?
|
Tomography, Emission-Computed | 2 | 2006 | 58 | 0.340 |
Why?
|
Fibroblasts | 6 | 2022 | 842 | 0.340 |
Why?
|
Feasibility Studies | 4 | 2018 | 749 | 0.330 |
Why?
|
ROC Curve | 5 | 2019 | 473 | 0.330 |
Why?
|
Autoimmune Diseases of the Nervous System | 1 | 2008 | 19 | 0.330 |
Why?
|
Birt-Hogg-Dube Syndrome | 4 | 2023 | 6 | 0.330 |
Why?
|
Bronchioles | 2 | 2019 | 23 | 0.330 |
Why?
|
Cross-Sectional Studies | 12 | 2022 | 4552 | 0.320 |
Why?
|
Sex Factors | 5 | 2018 | 1781 | 0.320 |
Why?
|
Histiocytosis, Langerhans-Cell | 4 | 2023 | 35 | 0.320 |
Why?
|
Practice Guidelines as Topic | 4 | 2021 | 1440 | 0.320 |
Why?
|
Clinical Decision-Making | 2 | 2021 | 278 | 0.310 |
Why?
|
Linear Models | 8 | 2018 | 827 | 0.310 |
Why?
|
Body Mass Index | 7 | 2018 | 2092 | 0.310 |
Why?
|
Pseudomonas Infections | 1 | 2009 | 193 | 0.310 |
Why?
|
Analysis of Variance | 5 | 2014 | 1293 | 0.310 |
Why?
|
Nitrogen Dioxide | 1 | 2007 | 32 | 0.310 |
Why?
|
Siblings | 1 | 2008 | 235 | 0.300 |
Why?
|
Radiology | 2 | 2014 | 199 | 0.300 |
Why?
|
Respiration | 5 | 2023 | 183 | 0.300 |
Why?
|
Schizophrenic Psychology | 3 | 2022 | 113 | 0.300 |
Why?
|
Nervous System Diseases | 2 | 2007 | 261 | 0.290 |
Why?
|
Receptors, Metabotropic Glutamate | 1 | 2007 | 35 | 0.290 |
Why?
|
Synapses | 2 | 2009 | 344 | 0.290 |
Why?
|
Autoimmune Diseases | 2 | 2024 | 398 | 0.290 |
Why?
|
Acute Disease | 6 | 2021 | 940 | 0.290 |
Why?
|
Animals | 22 | 2021 | 33381 | 0.290 |
Why?
|
Total Lung Capacity | 7 | 2020 | 33 | 0.290 |
Why?
|
alpha 1-Antitrypsin Deficiency | 2 | 2023 | 79 | 0.290 |
Why?
|
Neurologic Examination | 3 | 2012 | 126 | 0.290 |
Why?
|
Bronchography | 3 | 2013 | 10 | 0.290 |
Why?
|
Lymphangioleiomyomatosis | 3 | 2023 | 23 | 0.280 |
Why?
|
Alleles | 6 | 2019 | 832 | 0.280 |
Why?
|
Lung Volume Measurements | 3 | 2021 | 46 | 0.280 |
Why?
|
Walking | 3 | 2022 | 415 | 0.280 |
Why?
|
Child, Preschool | 11 | 2019 | 9491 | 0.280 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2011 | 968 | 0.270 |
Why?
|
Early Diagnosis | 5 | 2021 | 230 | 0.270 |
Why?
|
Hypoxia | 1 | 2012 | 963 | 0.260 |
Why?
|
Pregnancy Complications | 1 | 2010 | 448 | 0.260 |
Why?
|
Hippocampus | 3 | 2009 | 735 | 0.260 |
Why?
|
Mycobacterium Infections | 1 | 2005 | 61 | 0.260 |
Why?
|
Protein Subunits | 2 | 2021 | 211 | 0.260 |
Why?
|
Chronic Disease | 6 | 2022 | 1636 | 0.260 |
Why?
|
Airway Obstruction | 2 | 2019 | 168 | 0.260 |
Why?
|
beta Catenin | 1 | 2007 | 219 | 0.260 |
Why?
|
Protein Isoforms | 3 | 2019 | 345 | 0.260 |
Why?
|
Treatment Outcome | 12 | 2023 | 9342 | 0.260 |
Why?
|
Heart Defects, Congenital | 1 | 2012 | 703 | 0.260 |
Why?
|
Genetic Association Studies | 2 | 2019 | 371 | 0.260 |
Why?
|
Blood Glucose | 1 | 2014 | 1939 | 0.250 |
Why?
|
Logistic Models | 10 | 2018 | 1901 | 0.250 |
Why?
|
Dopamine | 2 | 2006 | 249 | 0.250 |
Why?
|
Radiopharmaceuticals | 2 | 2016 | 194 | 0.240 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 285 | 0.240 |
Why?
|
Solitary Pulmonary Nodule | 2 | 2016 | 26 | 0.240 |
Why?
|
Introns | 2 | 2023 | 234 | 0.240 |
Why?
|
Prevalence | 9 | 2023 | 2326 | 0.240 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2005 | 290 | 0.240 |
Why?
|
Survival Rate | 6 | 2018 | 1720 | 0.240 |
Why?
|
Tropanes | 1 | 2003 | 3 | 0.240 |
Why?
|
Cluster Analysis | 4 | 2019 | 481 | 0.230 |
Why?
|
Patient Advocacy | 1 | 2024 | 66 | 0.230 |
Why?
|
Organotechnetium Compounds | 1 | 2003 | 17 | 0.230 |
Why?
|
Mitochondrial Proteins | 2 | 2023 | 226 | 0.230 |
Why?
|
Motivation | 3 | 2022 | 506 | 0.230 |
Why?
|
Molecular Epidemiology | 2 | 2022 | 69 | 0.230 |
Why?
|
Incidence | 9 | 2023 | 2424 | 0.230 |
Why?
|
Exercise Test | 4 | 2016 | 551 | 0.230 |
Why?
|
International Cooperation | 4 | 2017 | 177 | 0.230 |
Why?
|
Blotting, Western | 4 | 2019 | 1194 | 0.230 |
Why?
|
Corpus Striatum | 2 | 2006 | 127 | 0.230 |
Why?
|
Contrast Media | 3 | 2020 | 373 | 0.230 |
Why?
|
Linoleic Acids | 1 | 2022 | 4 | 0.230 |
Why?
|
Rats | 6 | 2015 | 5392 | 0.230 |
Why?
|
Membrane Glycoproteins | 2 | 2015 | 446 | 0.220 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 105 | 0.220 |
Why?
|
Age of Onset | 6 | 2019 | 467 | 0.220 |
Why?
|
Blood Platelets | 2 | 2018 | 369 | 0.220 |
Why?
|
Carcinogens, Environmental | 1 | 2002 | 6 | 0.220 |
Why?
|
Clinical Trials as Topic | 6 | 2024 | 969 | 0.220 |
Why?
|
Models, Biological | 4 | 2017 | 1715 | 0.220 |
Why?
|
Asbestos | 1 | 2002 | 20 | 0.220 |
Why?
|
Promoter Regions, Genetic | 5 | 2019 | 1158 | 0.220 |
Why?
|
Ventricular Function | 2 | 2017 | 60 | 0.220 |
Why?
|
Diabetes Mellitus | 3 | 2016 | 942 | 0.210 |
Why?
|
Sjogren's Syndrome | 3 | 2019 | 40 | 0.210 |
Why?
|
Cerebral Cortex | 4 | 2018 | 416 | 0.210 |
Why?
|
Membrane Transport Proteins | 1 | 2003 | 137 | 0.210 |
Why?
|
Guanine | 3 | 2022 | 75 | 0.210 |
Why?
|
Chi-Square Distribution | 5 | 2013 | 525 | 0.210 |
Why?
|
Mesothelioma | 1 | 2002 | 32 | 0.210 |
Why?
|
Bleomycin | 3 | 2021 | 228 | 0.210 |
Why?
|
Antibodies | 2 | 2019 | 392 | 0.210 |
Why?
|
Time Factors | 9 | 2020 | 6412 | 0.210 |
Why?
|
Genetic Therapy | 2 | 2021 | 267 | 0.210 |
Why?
|
Bronchial Diseases | 2 | 2012 | 34 | 0.210 |
Why?
|
Environmental Exposure | 4 | 2020 | 405 | 0.210 |
Why?
|
Hypertension, Pulmonary | 5 | 2021 | 1794 | 0.210 |
Why?
|
Chromosome Deletion | 2 | 2015 | 95 | 0.210 |
Why?
|
Tomography Scanners, X-Ray Computed | 2 | 2017 | 18 | 0.210 |
Why?
|
Fibrosis | 7 | 2022 | 483 | 0.210 |
Why?
|
Cyclophosphamide | 3 | 2011 | 222 | 0.200 |
Why?
|
Societies, Medical | 8 | 2021 | 703 | 0.200 |
Why?
|
Carbon Monoxide | 3 | 2019 | 64 | 0.200 |
Why?
|
Symptom Flare Up | 1 | 2021 | 41 | 0.200 |
Why?
|
Retinoids | 1 | 2021 | 32 | 0.200 |
Why?
|
Proportional Hazards Models | 5 | 2022 | 1125 | 0.200 |
Why?
|
Olfaction Disorders | 1 | 2022 | 47 | 0.200 |
Why?
|
Respiration Disorders | 1 | 2021 | 66 | 0.200 |
Why?
|
Protein C | 1 | 2021 | 44 | 0.200 |
Why?
|
Pulmonary Surfactant-Associated Protein C | 1 | 2021 | 41 | 0.200 |
Why?
|
Scleroderma, Systemic | 3 | 2019 | 94 | 0.190 |
Why?
|
Statistics as Topic | 4 | 2012 | 307 | 0.190 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 811 | 0.190 |
Why?
|
Bacteriophages | 1 | 2022 | 76 | 0.190 |
Why?
|
RNA Stability | 1 | 2021 | 97 | 0.190 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2021 | 84 | 0.190 |
Why?
|
Brain | 3 | 2020 | 2490 | 0.190 |
Why?
|
Rhinitis | 1 | 2022 | 129 | 0.190 |
Why?
|
Adenine | 3 | 2022 | 223 | 0.190 |
Why?
|
Patient Care Management | 1 | 2021 | 57 | 0.190 |
Why?
|
RNA, Messenger | 5 | 2021 | 2657 | 0.190 |
Why?
|
DNA | 2 | 2018 | 1388 | 0.190 |
Why?
|
Mycobacterium abscessus | 1 | 2022 | 97 | 0.190 |
Why?
|
Cognitive Remediation | 1 | 2020 | 1 | 0.190 |
Why?
|
Age Factors | 4 | 2015 | 2995 | 0.190 |
Why?
|
Intermediate Filaments | 1 | 2020 | 46 | 0.190 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2022 | 499 | 0.180 |
Why?
|
Neurofilament Proteins | 1 | 2020 | 33 | 0.180 |
Why?
|
Parkinson Disease | 2 | 2006 | 334 | 0.180 |
Why?
|
Pilot Projects | 2 | 2022 | 1419 | 0.180 |
Why?
|
Recombinant Proteins | 2 | 2019 | 1308 | 0.180 |
Why?
|
Teratoma | 3 | 2010 | 92 | 0.180 |
Why?
|
Mice | 10 | 2021 | 15520 | 0.180 |
Why?
|
Pulmonary Medicine | 3 | 2015 | 85 | 0.180 |
Why?
|
Mice, Inbred C57BL | 5 | 2021 | 4908 | 0.180 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 195 | 0.180 |
Why?
|
Rare Diseases | 2 | 2018 | 113 | 0.180 |
Why?
|
Sensorimotor Cortex | 1 | 2019 | 2 | 0.180 |
Why?
|
Desmoplakins | 1 | 2019 | 19 | 0.180 |
Why?
|
Vasoconstriction | 1 | 2021 | 213 | 0.180 |
Why?
|
Health Resources | 1 | 2021 | 132 | 0.180 |
Why?
|
Hyperostosis | 1 | 2019 | 6 | 0.180 |
Why?
|
Afferent Pathways | 1 | 2019 | 44 | 0.180 |
Why?
|
DiGeorge Syndrome | 2 | 2012 | 21 | 0.180 |
Why?
|
Proprioception | 1 | 2019 | 19 | 0.180 |
Why?
|
Genetic Markers | 3 | 2021 | 348 | 0.170 |
Why?
|
Cigarette Smoking | 2 | 2020 | 85 | 0.170 |
Why?
|
Chromatography, Liquid | 3 | 2018 | 355 | 0.170 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2021 | 236 | 0.170 |
Why?
|
Racemases and Epimerases | 1 | 2018 | 11 | 0.170 |
Why?
|
Ambulatory Care Facilities | 1 | 2021 | 218 | 0.170 |
Why?
|
Indoles | 2 | 2019 | 316 | 0.170 |
Why?
|
Minimal Clinically Important Difference | 1 | 2018 | 7 | 0.170 |
Why?
|
Psychometrics | 1 | 2022 | 631 | 0.170 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2022 | 1244 | 0.170 |
Why?
|
Oral Hygiene | 1 | 2018 | 16 | 0.170 |
Why?
|
Iron Regulatory Protein 2 | 2 | 2015 | 7 | 0.170 |
Why?
|
Scleroderma, Limited | 2 | 2008 | 3 | 0.170 |
Why?
|
Sex Distribution | 5 | 2016 | 351 | 0.170 |
Why?
|
Cause of Death | 2 | 2018 | 380 | 0.160 |
Why?
|
Models, Theoretical | 2 | 2020 | 556 | 0.160 |
Why?
|
September 11 Terrorist Attacks | 1 | 2018 | 22 | 0.160 |
Why?
|
Genetic Loci | 3 | 2016 | 281 | 0.160 |
Why?
|
Membrane Proteins | 2 | 2015 | 1055 | 0.160 |
Why?
|
Air Pollutants, Occupational | 1 | 2018 | 33 | 0.160 |
Why?
|
Apolipoprotein A-I | 1 | 2018 | 26 | 0.160 |
Why?
|
Self-Help Devices | 1 | 2018 | 19 | 0.160 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 245 | 0.160 |
Why?
|
Carrier Proteins | 3 | 2015 | 726 | 0.160 |
Why?
|
Fatigue | 1 | 2019 | 297 | 0.160 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 356 | 0.160 |
Why?
|
Traction | 3 | 2023 | 19 | 0.160 |
Why?
|
Societies | 1 | 2017 | 42 | 0.160 |
Why?
|
Genomic Instability | 1 | 2017 | 38 | 0.160 |
Why?
|
Respiratory System | 2 | 2016 | 141 | 0.160 |
Why?
|
Pleura | 2 | 2015 | 18 | 0.150 |
Why?
|
Cryptogenic Organizing Pneumonia | 2 | 2009 | 17 | 0.150 |
Why?
|
Spine | 1 | 2019 | 144 | 0.150 |
Why?
|
Premature Birth | 2 | 2012 | 284 | 0.150 |
Why?
|
Cardiac Volume | 1 | 2017 | 12 | 0.150 |
Why?
|
Motion | 1 | 2017 | 95 | 0.150 |
Why?
|
Vascular Calcification | 1 | 2019 | 123 | 0.150 |
Why?
|
Computed Tomography Angiography | 1 | 2018 | 81 | 0.150 |
Why?
|
Principal Component Analysis | 1 | 2017 | 180 | 0.150 |
Why?
|
Parenchymal Tissue | 1 | 2016 | 7 | 0.150 |
Why?
|
Nursing Homes | 1 | 2018 | 130 | 0.150 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 2022 | 334 | 0.150 |
Why?
|
Bronchiolitis Obliterans | 2 | 2009 | 66 | 0.150 |
Why?
|
Bayes Theorem | 2 | 2022 | 344 | 0.150 |
Why?
|
Complement C3 | 1 | 2018 | 192 | 0.150 |
Why?
|
Pneumonia | 4 | 2013 | 592 | 0.150 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 239 | 0.150 |
Why?
|
Evidence-Based Medicine | 3 | 2021 | 693 | 0.150 |
Why?
|
Calibration | 1 | 2017 | 135 | 0.140 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 336 | 0.140 |
Why?
|
Artificial Intelligence | 2 | 2021 | 140 | 0.140 |
Why?
|
Creatine | 1 | 2016 | 56 | 0.140 |
Why?
|
Program Evaluation | 1 | 2021 | 845 | 0.140 |
Why?
|
Mucociliary Clearance | 1 | 2016 | 43 | 0.140 |
Why?
|
Software Validation | 1 | 2016 | 7 | 0.140 |
Why?
|
Referral and Consultation | 1 | 2021 | 648 | 0.140 |
Why?
|
Arthritis, Experimental | 1 | 2018 | 133 | 0.140 |
Why?
|
Pulmonary Alveoli | 2 | 2016 | 384 | 0.140 |
Why?
|
HLA-DQ beta-Chains | 1 | 2016 | 61 | 0.140 |
Why?
|
Republic of Korea | 3 | 2023 | 26 | 0.140 |
Why?
|
Loss of Heterozygosity | 1 | 2016 | 40 | 0.140 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2015 | 26 | 0.140 |
Why?
|
Tracheal Diseases | 1 | 2016 | 16 | 0.140 |
Why?
|
Mitochondrial Diseases | 1 | 2016 | 79 | 0.140 |
Why?
|
Respiratory Insufficiency | 2 | 2017 | 290 | 0.140 |
Why?
|
HLA-DRB1 Chains | 1 | 2016 | 97 | 0.140 |
Why?
|
Reference Values | 3 | 2013 | 774 | 0.140 |
Why?
|
Oxidative Phosphorylation | 1 | 2016 | 156 | 0.140 |
Why?
|
Pleural Diseases | 1 | 2015 | 21 | 0.140 |
Why?
|
Occupational Health | 1 | 2018 | 172 | 0.140 |
Why?
|
Genomics | 1 | 2021 | 706 | 0.140 |
Why?
|
Guanylate Kinases | 1 | 2015 | 14 | 0.140 |
Why?
|
ELAV Proteins | 1 | 2015 | 17 | 0.140 |
Why?
|
Neoplasm Staging | 3 | 2011 | 1223 | 0.140 |
Why?
|
Disks Large Homolog 4 Protein | 1 | 2015 | 18 | 0.130 |
Why?
|
Sildenafil Citrate | 1 | 2015 | 57 | 0.130 |
Why?
|
Multicenter Studies as Topic | 2 | 2014 | 253 | 0.130 |
Why?
|
Collagen | 1 | 2018 | 433 | 0.130 |
Why?
|
Azathioprine | 1 | 2015 | 51 | 0.130 |
Why?
|
Transcription Elongation, Genetic | 1 | 2015 | 20 | 0.130 |
Why?
|
Protein Biosynthesis | 1 | 2017 | 397 | 0.130 |
Why?
|
Interferon-beta | 2 | 2008 | 82 | 0.130 |
Why?
|
Cognitive Dysfunction | 1 | 2020 | 301 | 0.130 |
Why?
|
Electrocardiography | 3 | 2017 | 556 | 0.130 |
Why?
|
Galactosylceramidase | 1 | 2015 | 4 | 0.130 |
Why?
|
Proteomics | 2 | 2021 | 876 | 0.130 |
Why?
|
Gene Expression Regulation | 4 | 2018 | 2445 | 0.130 |
Why?
|
Cerebellum | 2 | 2015 | 203 | 0.130 |
Why?
|
Epithelial Cells | 1 | 2021 | 963 | 0.130 |
Why?
|
Inflammation Mediators | 1 | 2018 | 502 | 0.130 |
Why?
|
Cryopreservation | 1 | 2016 | 99 | 0.130 |
Why?
|
Transcriptome | 2 | 2018 | 756 | 0.130 |
Why?
|
Adenocarcinoma | 2 | 2012 | 812 | 0.130 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2019 | 667 | 0.130 |
Why?
|
Glucose Tolerance Test | 1 | 2016 | 368 | 0.130 |
Why?
|
Mycobacterium avium Complex | 1 | 2016 | 93 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 348 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 339 | 0.130 |
Why?
|
Comparative Effectiveness Research | 1 | 2016 | 132 | 0.130 |
Why?
|
Axonemal Dyneins | 1 | 2014 | 8 | 0.130 |
Why?
|
DNA Copy Number Variations | 1 | 2015 | 167 | 0.130 |
Why?
|
Gene Silencing | 1 | 2015 | 177 | 0.130 |
Why?
|
Brain Stem | 1 | 2015 | 104 | 0.130 |
Why?
|
Physicians | 2 | 2022 | 794 | 0.130 |
Why?
|
Military Personnel | 1 | 2022 | 529 | 0.130 |
Why?
|
Prednisone | 1 | 2015 | 235 | 0.130 |
Why?
|
Embryo, Mammalian | 1 | 2015 | 220 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 842 | 0.120 |
Why?
|
Catechol O-Methyltransferase | 2 | 2004 | 17 | 0.120 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2007 | 341 | 0.120 |
Why?
|
Tyrosine | 2 | 2005 | 233 | 0.120 |
Why?
|
Spinal Fractures | 1 | 2015 | 77 | 0.120 |
Why?
|
Immunosuppressive Agents | 3 | 2015 | 681 | 0.120 |
Why?
|
Mass Chest X-Ray | 2 | 2010 | 4 | 0.120 |
Why?
|
Myocardium | 1 | 2019 | 970 | 0.120 |
Why?
|
Age Distribution | 3 | 2016 | 362 | 0.120 |
Why?
|
Multidetector Computed Tomography | 3 | 2019 | 27 | 0.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 1390 | 0.120 |
Why?
|
Contrast Sensitivity | 1 | 2013 | 13 | 0.120 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2010 | 1945 | 0.120 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2013 | 23 | 0.120 |
Why?
|
Anisotropy | 1 | 2013 | 65 | 0.120 |
Why?
|
Erythrocytes | 1 | 2018 | 641 | 0.110 |
Why?
|
Protons | 1 | 2013 | 79 | 0.110 |
Why?
|
Heart Ventricles | 2 | 2017 | 727 | 0.110 |
Why?
|
Liver | 2 | 2020 | 1816 | 0.110 |
Why?
|
Qc-SNARE Proteins | 1 | 2012 | 7 | 0.110 |
Why?
|
Qb-SNARE Proteins | 1 | 2012 | 6 | 0.110 |
Why?
|
Research Design | 3 | 2022 | 969 | 0.110 |
Why?
|
Inflammation | 4 | 2018 | 2566 | 0.110 |
Why?
|
Respiratory Mechanics | 1 | 2013 | 60 | 0.110 |
Why?
|
Elastic Modulus | 1 | 2013 | 118 | 0.110 |
Why?
|
Iopamidol | 1 | 2012 | 13 | 0.110 |
Why?
|
Coronary Artery Disease | 1 | 2019 | 647 | 0.110 |
Why?
|
Fasting | 1 | 2014 | 264 | 0.110 |
Why?
|
Blood Cells | 1 | 2012 | 39 | 0.110 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2014 | 177 | 0.110 |
Why?
|
Tomography, Optical Coherence | 1 | 2013 | 126 | 0.110 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 387 | 0.110 |
Why?
|
Ventricular Dysfunction | 1 | 2012 | 15 | 0.110 |
Why?
|
Dextrocardia | 1 | 2012 | 3 | 0.110 |
Why?
|
Mental Disorders | 1 | 2020 | 939 | 0.110 |
Why?
|
Osteoporosis | 1 | 2015 | 229 | 0.110 |
Why?
|
Cilia | 1 | 2013 | 160 | 0.100 |
Why?
|
Disease Models, Animal | 2 | 2020 | 3730 | 0.100 |
Why?
|
Paraneoplastic Syndromes, Nervous System | 2 | 2008 | 8 | 0.100 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2012 | 114 | 0.100 |
Why?
|
Blood Vessels | 1 | 2013 | 187 | 0.100 |
Why?
|
Stress, Mechanical | 1 | 2013 | 443 | 0.100 |
Why?
|
Diastole | 1 | 2011 | 145 | 0.100 |
Why?
|
Consensus | 1 | 2013 | 534 | 0.100 |
Why?
|
Bone Density | 1 | 2015 | 449 | 0.100 |
Why?
|
Patient Care Team | 1 | 2016 | 521 | 0.100 |
Why?
|
Sarcoma, Kaposi | 1 | 2012 | 73 | 0.100 |
Why?
|
Heart Atria | 1 | 2012 | 112 | 0.100 |
Why?
|
Methotrexate | 1 | 2012 | 227 | 0.100 |
Why?
|
Sodium Chloride | 1 | 2012 | 144 | 0.100 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2022 | 57 | 0.100 |
Why?
|
Miniature Postsynaptic Potentials | 1 | 2010 | 9 | 0.100 |
Why?
|
Cisplatin | 1 | 2012 | 271 | 0.100 |
Why?
|
Bronchoscopy | 3 | 2021 | 247 | 0.100 |
Why?
|
Cell Line | 3 | 2016 | 2707 | 0.100 |
Why?
|
Apgar Score | 1 | 2010 | 16 | 0.090 |
Why?
|
Hepatectomy | 1 | 2011 | 139 | 0.090 |
Why?
|
Term Birth | 1 | 2010 | 17 | 0.090 |
Why?
|
Aminophenols | 2 | 2022 | 112 | 0.090 |
Why?
|
Inflammasomes | 1 | 2012 | 120 | 0.090 |
Why?
|
Live Birth | 1 | 2010 | 47 | 0.090 |
Why?
|
Peptides, Cyclic | 1 | 2012 | 260 | 0.090 |
Why?
|
Patient Reported Outcome Measures | 2 | 2022 | 252 | 0.090 |
Why?
|
Hemoptysis | 1 | 2010 | 39 | 0.090 |
Why?
|
Leg | 1 | 2012 | 234 | 0.090 |
Why?
|
Speech Disorders | 1 | 2010 | 35 | 0.090 |
Why?
|
Scleroderma, Localized | 1 | 2009 | 6 | 0.090 |
Why?
|
alpha7 Nicotinic Acetylcholine Receptor | 1 | 2010 | 105 | 0.090 |
Why?
|
Walk Test | 2 | 2021 | 49 | 0.090 |
Why?
|
Polymyositis | 1 | 2009 | 14 | 0.090 |
Why?
|
Aorta | 1 | 2012 | 367 | 0.090 |
Why?
|
Excitatory Postsynaptic Potentials | 1 | 2010 | 105 | 0.090 |
Why?
|
Registries | 2 | 2017 | 1810 | 0.090 |
Why?
|
Patch-Clamp Techniques | 1 | 2010 | 247 | 0.090 |
Why?
|
Autoimmunity | 2 | 2015 | 831 | 0.090 |
Why?
|
Reactive Oxygen Species | 1 | 2012 | 576 | 0.090 |
Why?
|
X-Ray Microtomography | 2 | 2021 | 79 | 0.090 |
Why?
|
Chromosomes, Human, Pair 22 | 2 | 2006 | 39 | 0.090 |
Why?
|
Infant | 4 | 2019 | 8293 | 0.090 |
Why?
|
Survivors | 1 | 2013 | 418 | 0.090 |
Why?
|
Gene Expression Profiling | 4 | 2018 | 1597 | 0.090 |
Why?
|
Salivary Glands, Minor | 1 | 2009 | 6 | 0.090 |
Why?
|
Exercise Tolerance | 3 | 2016 | 233 | 0.090 |
Why?
|
Abortion, Spontaneous | 1 | 2010 | 94 | 0.090 |
Why?
|
Limbic Encephalitis | 1 | 2009 | 3 | 0.090 |
Why?
|
Antibodies, Antinuclear | 1 | 2009 | 55 | 0.090 |
Why?
|
alpha-Synuclein | 2 | 2006 | 29 | 0.090 |
Why?
|
Amino Acyl-tRNA Synthetases | 1 | 2009 | 25 | 0.090 |
Why?
|
Acute Lung Injury | 1 | 2013 | 310 | 0.090 |
Why?
|
Delivery, Obstetric | 1 | 2010 | 125 | 0.090 |
Why?
|
Spondylitis, Ankylosing | 1 | 2009 | 42 | 0.090 |
Why?
|
Speech | 1 | 2010 | 76 | 0.090 |
Why?
|
Autoantigens | 2 | 2009 | 397 | 0.080 |
Why?
|
Arrhythmias, Cardiac | 1 | 2011 | 277 | 0.080 |
Why?
|
Up-Regulation | 1 | 2012 | 872 | 0.080 |
Why?
|
Neurocognitive Disorders | 1 | 2008 | 25 | 0.080 |
Why?
|
Axons | 1 | 2010 | 185 | 0.080 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2016 | 131 | 0.080 |
Why?
|
Scleroderma, Diffuse | 1 | 2008 | 4 | 0.080 |
Why?
|
DNA, Mitochondrial | 1 | 2010 | 187 | 0.080 |
Why?
|
Tandem Repeat Sequences | 1 | 2008 | 18 | 0.080 |
Why?
|
Hospitalization | 2 | 2014 | 1785 | 0.080 |
Why?
|
Calcium Signaling | 1 | 2010 | 219 | 0.080 |
Why?
|
Tobacco Use Disorder | 1 | 2011 | 233 | 0.080 |
Why?
|
Europe | 3 | 2015 | 356 | 0.080 |
Why?
|
Insulin | 3 | 2014 | 2162 | 0.080 |
Why?
|
Radiography | 4 | 2004 | 861 | 0.080 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2011 | 344 | 0.080 |
Why?
|
Combined Modality Therapy | 1 | 2011 | 1166 | 0.080 |
Why?
|
Catheter Ablation | 1 | 2011 | 286 | 0.080 |
Why?
|
Receptors, AMPA | 1 | 2009 | 125 | 0.080 |
Why?
|
Neurotoxins | 1 | 2007 | 27 | 0.080 |
Why?
|
Sulfonamides | 1 | 2011 | 445 | 0.080 |
Why?
|
DNA Methylation | 1 | 2012 | 503 | 0.080 |
Why?
|
Cytoprotection | 1 | 2007 | 55 | 0.080 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2024 | 115 | 0.080 |
Why?
|
Antihypertensive Agents | 1 | 2011 | 437 | 0.080 |
Why?
|
Community Medicine | 1 | 2007 | 5 | 0.080 |
Why?
|
Activities of Daily Living | 1 | 2010 | 354 | 0.070 |
Why?
|
Area Under Curve | 2 | 2018 | 296 | 0.070 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2009 | 227 | 0.070 |
Why?
|
Muscle, Skeletal | 1 | 2016 | 1515 | 0.070 |
Why?
|
Birth Weight | 1 | 2010 | 465 | 0.070 |
Why?
|
Phosphorylation | 2 | 2016 | 1633 | 0.070 |
Why?
|
Ovarian Neoplasms | 2 | 2010 | 420 | 0.070 |
Why?
|
Pericardium | 1 | 2007 | 50 | 0.070 |
Why?
|
Japan | 2 | 2021 | 97 | 0.070 |
Why?
|
Pneumonectomy | 2 | 2023 | 115 | 0.070 |
Why?
|
Cyclin-Dependent Kinase 5 | 1 | 2006 | 3 | 0.070 |
Why?
|
Sodium-Calcium Exchanger | 1 | 2006 | 14 | 0.070 |
Why?
|
Neuroprotective Agents | 1 | 2007 | 111 | 0.070 |
Why?
|
Inositol 1,4,5-Trisphosphate Receptors | 1 | 2006 | 26 | 0.070 |
Why?
|
Statistics, Nonparametric | 1 | 2007 | 403 | 0.070 |
Why?
|
Epitopes | 1 | 2008 | 443 | 0.070 |
Why?
|
Internationality | 2 | 2017 | 152 | 0.070 |
Why?
|
United Kingdom | 2 | 2019 | 236 | 0.070 |
Why?
|
Antineoplastic Agents | 2 | 2019 | 1974 | 0.070 |
Why?
|
Cytosol | 1 | 2006 | 221 | 0.070 |
Why?
|
Mycophenolic Acid | 1 | 2006 | 79 | 0.070 |
Why?
|
HEK293 Cells | 2 | 2018 | 625 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2019 | 453 | 0.070 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 175 | 0.070 |
Why?
|
Conotoxins | 1 | 2005 | 4 | 0.070 |
Why?
|
MicroRNAs | 1 | 2012 | 637 | 0.070 |
Why?
|
Administration, Inhalation | 1 | 2007 | 656 | 0.070 |
Why?
|
Organ Size | 2 | 2016 | 460 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2011 | 610 | 0.070 |
Why?
|
Cognition | 2 | 2021 | 1024 | 0.070 |
Why?
|
Amino Acid Sequence | 2 | 2020 | 2071 | 0.070 |
Why?
|
Length of Stay | 1 | 2010 | 1032 | 0.070 |
Why?
|
Calcium Channels, L-Type | 1 | 2006 | 110 | 0.070 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 2019 | 332 | 0.070 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2005 | 90 | 0.060 |
Why?
|
Receptors, Neurotransmitter | 1 | 2004 | 16 | 0.060 |
Why?
|
Calcineurin | 1 | 2005 | 95 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2012 | 762 | 0.060 |
Why?
|
Epilepsy | 1 | 2008 | 290 | 0.060 |
Why?
|
Nitrates | 1 | 2004 | 78 | 0.060 |
Why?
|
Protein Structure, Quaternary | 1 | 2004 | 116 | 0.060 |
Why?
|
Immunoprecipitation | 2 | 2018 | 161 | 0.060 |
Why?
|
Synaptic Transmission | 1 | 2006 | 239 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2007 | 422 | 0.060 |
Why?
|
Granuloma | 1 | 2004 | 87 | 0.060 |
Why?
|
Ventricular Function, Right | 1 | 2006 | 257 | 0.060 |
Why?
|
Smoking Cessation | 2 | 2018 | 360 | 0.060 |
Why?
|
Residual Volume | 1 | 2023 | 7 | 0.060 |
Why?
|
Monoamine Oxidase | 1 | 2003 | 25 | 0.060 |
Why?
|
Textile Industry | 1 | 2003 | 1 | 0.060 |
Why?
|
Amino Acid Substitution | 2 | 2019 | 276 | 0.060 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 304 | 0.060 |
Why?
|
Minisatellite Repeats | 1 | 2003 | 38 | 0.060 |
Why?
|
Microscopy, Fluorescence | 1 | 2005 | 412 | 0.060 |
Why?
|
Tomography | 1 | 2023 | 23 | 0.060 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 1 | 2003 | 40 | 0.060 |
Why?
|
Induced Pluripotent Stem Cells | 2 | 2016 | 185 | 0.060 |
Why?
|
Enzyme Activation | 1 | 2005 | 828 | 0.060 |
Why?
|
Gene Expression | 3 | 2017 | 1489 | 0.060 |
Why?
|
Unsupervised Machine Learning | 1 | 2022 | 8 | 0.060 |
Why?
|
Muscle Spasticity | 1 | 2023 | 53 | 0.060 |
Why?
|
Coenzyme A | 1 | 2022 | 6 | 0.060 |
Why?
|
Phosphatidylglycerols | 1 | 2022 | 20 | 0.050 |
Why?
|
Carcinoma, Bronchogenic | 1 | 2002 | 17 | 0.050 |
Why?
|
3-Hydroxybutyric Acid | 1 | 2022 | 15 | 0.050 |
Why?
|
Antacids | 1 | 2022 | 15 | 0.050 |
Why?
|
Cardiovascular Diseases | 1 | 2014 | 1798 | 0.050 |
Why?
|
Silicosis | 1 | 2002 | 21 | 0.050 |
Why?
|
Lymphocytes | 2 | 2017 | 347 | 0.050 |
Why?
|
Sulfur | 1 | 2022 | 44 | 0.050 |
Why?
|
Carnitine | 1 | 2022 | 65 | 0.050 |
Why?
|
Neurosecretory Systems | 1 | 2002 | 33 | 0.050 |
Why?
|
Pyridones | 1 | 2023 | 119 | 0.050 |
Why?
|
Protein Processing, Post-Translational | 1 | 2004 | 408 | 0.050 |
Why?
|
Oxygen | 2 | 2023 | 854 | 0.050 |
Why?
|
Ceramides | 1 | 2022 | 104 | 0.050 |
Why?
|
Australia | 1 | 2022 | 212 | 0.050 |
Why?
|
5' Untranslated Regions | 1 | 2021 | 52 | 0.050 |
Why?
|
Pulmonologists | 1 | 2021 | 15 | 0.050 |
Why?
|
Hyperplasia | 1 | 2002 | 170 | 0.050 |
Why?
|
Benchmarking | 1 | 2023 | 172 | 0.050 |
Why?
|
Probability | 1 | 2022 | 305 | 0.050 |
Why?
|
Cell Differentiation | 3 | 2016 | 1753 | 0.050 |
Why?
|
Belgium | 1 | 2021 | 9 | 0.050 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2022 | 155 | 0.050 |
Why?
|
Oligonucleotides, Antisense | 1 | 2021 | 100 | 0.050 |
Why?
|
Poland | 1 | 2021 | 29 | 0.050 |
Why?
|
Research | 1 | 2005 | 411 | 0.050 |
Why?
|
Prefrontal Cortex | 1 | 2004 | 275 | 0.050 |
Why?
|
Aldehyde Oxidoreductases | 1 | 2021 | 32 | 0.050 |
Why?
|
Spain | 1 | 2021 | 34 | 0.050 |
Why?
|
Sweden | 1 | 2021 | 63 | 0.050 |
Why?
|
Radiologists | 1 | 2021 | 38 | 0.050 |
Why?
|
Fractals | 1 | 2021 | 6 | 0.050 |
Why?
|
Finland | 1 | 2021 | 71 | 0.050 |
Why?
|
3' Untranslated Regions | 1 | 2021 | 142 | 0.050 |
Why?
|
Germany | 1 | 2021 | 89 | 0.050 |
Why?
|
Protein Array Analysis | 1 | 2021 | 63 | 0.050 |
Why?
|
Protective Factors | 1 | 2021 | 92 | 0.050 |
Why?
|
New York | 1 | 2021 | 118 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2007 | 1323 | 0.050 |
Why?
|
Surface-Active Agents | 1 | 2021 | 81 | 0.050 |
Why?
|
Observational Studies as Topic | 1 | 2021 | 89 | 0.050 |
Why?
|
Iceland | 1 | 2020 | 6 | 0.050 |
Why?
|
Endpoint Determination | 2 | 2011 | 69 | 0.050 |
Why?
|
Hemodynamics | 2 | 2021 | 1004 | 0.050 |
Why?
|
Iron | 1 | 2022 | 248 | 0.050 |
Why?
|
Risk Adjustment | 1 | 2021 | 79 | 0.050 |
Why?
|
Polymerase Chain Reaction | 1 | 2003 | 1012 | 0.050 |
Why?
|
Neuropsychological Tests | 2 | 2021 | 1032 | 0.050 |
Why?
|
Mortality | 1 | 2002 | 299 | 0.050 |
Why?
|
Triglycerides | 1 | 2022 | 519 | 0.050 |
Why?
|
Canada | 1 | 2021 | 340 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2013 | 755 | 0.050 |
Why?
|
Liquid Biopsy | 1 | 2019 | 6 | 0.050 |
Why?
|
Tobacco Smoke Pollution | 2 | 2014 | 233 | 0.040 |
Why?
|
Air | 1 | 2020 | 48 | 0.040 |
Why?
|
Anthropometry | 1 | 2020 | 194 | 0.040 |
Why?
|
Macaca fascicularis | 1 | 2019 | 53 | 0.040 |
Why?
|
Acrylamides | 1 | 2019 | 42 | 0.040 |
Why?
|
Aniline Compounds | 1 | 2019 | 71 | 0.040 |
Why?
|
Ireland | 1 | 2019 | 25 | 0.040 |
Why?
|
Image Enhancement | 1 | 2020 | 181 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2010 | 5255 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2019 | 184 | 0.040 |
Why?
|
Dermatomyositis | 1 | 2019 | 22 | 0.040 |
Why?
|
Molecular Weight | 1 | 2019 | 343 | 0.040 |
Why?
|
Magnetoencephalography | 1 | 2019 | 103 | 0.040 |
Why?
|
Iowa | 1 | 2018 | 26 | 0.040 |
Why?
|
Histones | 2 | 2015 | 552 | 0.040 |
Why?
|
Fingers | 1 | 2019 | 83 | 0.040 |
Why?
|
Reference Standards | 1 | 2019 | 176 | 0.040 |
Why?
|
Pyrimidines | 1 | 2022 | 382 | 0.040 |
Why?
|
Colorado | 2 | 2019 | 4196 | 0.040 |
Why?
|
Dental Hygienists | 1 | 2018 | 15 | 0.040 |
Why?
|
Job Description | 1 | 2018 | 12 | 0.040 |
Why?
|
Treatment Failure | 1 | 2019 | 341 | 0.040 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2019 | 333 | 0.040 |
Why?
|
A549 Cells | 1 | 2018 | 48 | 0.040 |
Why?
|
Heart Failure | 1 | 2011 | 1969 | 0.040 |
Why?
|
Primary Cell Culture | 1 | 2018 | 155 | 0.040 |
Why?
|
Pregnancy | 1 | 2010 | 5691 | 0.040 |
Why?
|
Hep G2 Cells | 1 | 2018 | 73 | 0.040 |
Why?
|
Acetylation | 1 | 2018 | 217 | 0.040 |
Why?
|
Species Specificity | 1 | 2019 | 565 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 270 | 0.040 |
Why?
|
Gene Ontology | 1 | 2017 | 55 | 0.040 |
Why?
|
Simvastatin | 1 | 2018 | 65 | 0.040 |
Why?
|
Rheumatology | 1 | 2019 | 87 | 0.040 |
Why?
|
Neural Pathways | 1 | 2019 | 277 | 0.040 |
Why?
|
Telomerase | 1 | 2019 | 207 | 0.040 |
Why?
|
Netherlands | 1 | 2017 | 62 | 0.040 |
Why?
|
Death Certificates | 1 | 2017 | 28 | 0.040 |
Why?
|
Betacoronavirus | 1 | 2020 | 254 | 0.040 |
Why?
|
Syndrome | 2 | 2009 | 344 | 0.040 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 101 | 0.040 |
Why?
|
Phosphocreatine | 1 | 2016 | 37 | 0.040 |
Why?
|
Forecasting | 1 | 2019 | 353 | 0.040 |
Why?
|
Signal Transduction | 2 | 2007 | 4709 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2002 | 900 | 0.040 |
Why?
|
Uncertainty | 1 | 2017 | 101 | 0.040 |
Why?
|
Heart | 1 | 2020 | 631 | 0.040 |
Why?
|
Patient Selection | 1 | 2020 | 676 | 0.040 |
Why?
|
Bronchial Neoplasms | 1 | 2016 | 14 | 0.040 |
Why?
|
Models, Anatomic | 1 | 2017 | 94 | 0.040 |
Why?
|
Radiation Protection | 1 | 2016 | 36 | 0.040 |
Why?
|
Victoria | 1 | 2016 | 13 | 0.040 |
Why?
|
Papilloma | 1 | 2016 | 46 | 0.040 |
Why?
|
Tracheal Neoplasms | 1 | 2016 | 12 | 0.040 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2016 | 25 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2016 | 47 | 0.040 |
Why?
|
Phantoms, Imaging | 1 | 2017 | 139 | 0.040 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 254 | 0.040 |
Why?
|
Amyloidosis | 1 | 2016 | 40 | 0.030 |
Why?
|
Asbestosis | 1 | 2015 | 13 | 0.030 |
Why?
|
Inhalation | 1 | 2016 | 27 | 0.030 |
Why?
|
ErbB Receptors | 1 | 2019 | 569 | 0.030 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2017 | 154 | 0.030 |
Why?
|
Rheumatoid Factor | 1 | 2017 | 156 | 0.030 |
Why?
|
Xenon Isotopes | 1 | 2015 | 3 | 0.030 |
Why?
|
Helium | 1 | 2015 | 8 | 0.030 |
Why?
|
Thoracic Surgical Procedures | 1 | 2016 | 64 | 0.030 |
Why?
|
Fluorine | 1 | 2015 | 15 | 0.030 |
Why?
|
Causality | 1 | 2016 | 109 | 0.030 |
Why?
|
Serpins | 1 | 2015 | 26 | 0.030 |
Why?
|
Isotopes | 1 | 2015 | 26 | 0.030 |
Why?
|
Mitochondria, Muscle | 1 | 2016 | 97 | 0.030 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2015 | 36 | 0.030 |
Why?
|
Linkage Disequilibrium | 1 | 2016 | 273 | 0.030 |
Why?
|
Transfection | 2 | 2009 | 888 | 0.030 |
Why?
|
Recurrence | 2 | 2012 | 975 | 0.030 |
Why?
|
Markov Chains | 1 | 2015 | 118 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2018 | 580 | 0.030 |
Why?
|
Software | 1 | 2020 | 613 | 0.030 |
Why?
|
Aconitate Hydratase | 1 | 2015 | 17 | 0.030 |
Why?
|
GTPase-Activating Proteins | 1 | 2015 | 71 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2016 | 104 | 0.030 |
Why?
|
K562 Cells | 1 | 2015 | 73 | 0.030 |
Why?
|
Zinc Fingers | 1 | 2015 | 46 | 0.030 |
Why?
|
Perfusion | 1 | 2015 | 153 | 0.030 |
Why?
|
Physical Examination | 1 | 2016 | 243 | 0.030 |
Why?
|
Specimen Handling | 1 | 2016 | 165 | 0.030 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2014 | 31 | 0.030 |
Why?
|
Endodeoxyribonucleases | 1 | 2015 | 60 | 0.030 |
Why?
|
Respiratory Mucosa | 1 | 2016 | 254 | 0.030 |
Why?
|
Hemochromatosis Protein | 1 | 2014 | 3 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2015 | 233 | 0.030 |
Why?
|
Mexico | 1 | 2014 | 165 | 0.030 |
Why?
|
Acyl Coenzyme A | 1 | 2013 | 30 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2014 | 78 | 0.030 |
Why?
|
Computational Biology | 1 | 2018 | 588 | 0.030 |
Why?
|
Propionates | 1 | 2013 | 35 | 0.030 |
Why?
|
Nitrogen Isotopes | 1 | 2013 | 55 | 0.030 |
Why?
|
Computer Simulation | 1 | 2018 | 922 | 0.030 |
Why?
|
Hypercholesterolemia | 1 | 2014 | 93 | 0.030 |
Why?
|
Esters | 1 | 2013 | 61 | 0.030 |
Why?
|
Carbon Isotopes | 1 | 2013 | 115 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2018 | 699 | 0.030 |
Why?
|
Isotope Labeling | 1 | 2013 | 76 | 0.030 |
Why?
|
Models, Organizational | 1 | 2014 | 146 | 0.030 |
Why?
|
Patient Safety | 1 | 2016 | 281 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2015 | 289 | 0.030 |
Why?
|
Chromosomes, Human | 1 | 2013 | 41 | 0.030 |
Why?
|
Mental Recall | 1 | 2014 | 180 | 0.030 |
Why?
|
Biomarkers, Tumor | 1 | 2019 | 1059 | 0.030 |
Why?
|
APACHE | 1 | 2013 | 61 | 0.030 |
Why?
|
Swine | 1 | 2015 | 730 | 0.030 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2012 | 22 | 0.030 |
Why?
|
Health Services | 1 | 2013 | 110 | 0.030 |
Why?
|
Observation | 1 | 2012 | 50 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2022 | 1510 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 965 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2012 | 57 | 0.030 |
Why?
|
Aortography | 1 | 2012 | 52 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2013 | 204 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2012 | 115 | 0.030 |
Why?
|
Mixed Connective Tissue Disease | 1 | 2012 | 8 | 0.030 |
Why?
|
Disease Management | 1 | 2016 | 571 | 0.030 |
Why?
|
Arthrography | 1 | 2011 | 22 | 0.030 |
Why?
|
Neoplasms | 2 | 2021 | 2179 | 0.030 |
Why?
|
Graves Disease | 1 | 2012 | 32 | 0.030 |
Why?
|
Antigens, CD34 | 1 | 2012 | 98 | 0.030 |
Why?
|
Genetic Counseling | 1 | 2012 | 66 | 0.030 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 2012 | 103 | 0.030 |
Why?
|
Gene Frequency | 1 | 2013 | 513 | 0.030 |
Why?
|
Sulfhydryl Compounds | 1 | 2013 | 179 | 0.030 |
Why?
|
Odds Ratio | 1 | 2014 | 996 | 0.030 |
Why?
|
Herpesvirus 8, Human | 1 | 2012 | 68 | 0.030 |
Why?
|
Pedigree | 1 | 2013 | 485 | 0.030 |
Why?
|
Exome | 1 | 2012 | 220 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2012 | 510 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2018 | 2680 | 0.030 |
Why?
|
Education | 1 | 2012 | 105 | 0.030 |
Why?
|
Expert Testimony | 1 | 2011 | 56 | 0.030 |
Why?
|
Caspase 1 | 1 | 2012 | 143 | 0.020 |
Why?
|
Joints | 1 | 2011 | 85 | 0.020 |
Why?
|
Drug Synergism | 1 | 2012 | 339 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2015 | 545 | 0.020 |
Why?
|
Latin America | 1 | 2011 | 74 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2013 | 770 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 106 | 0.020 |
Why?
|
NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2012 | 150 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2010 | 103 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2012 | 218 | 0.020 |
Why?
|
Chest Pain | 1 | 2010 | 84 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2007 | 2851 | 0.020 |
Why?
|
Alanine-tRNA Ligase | 1 | 2009 | 3 | 0.020 |
Why?
|
Threonine-tRNA Ligase | 1 | 2009 | 3 | 0.020 |
Why?
|
Placebos | 1 | 2009 | 202 | 0.020 |
Why?
|
Administration, Oral | 1 | 2011 | 756 | 0.020 |
Why?
|
Minority Groups | 1 | 2010 | 237 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2013 | 635 | 0.020 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2008 | 15 | 0.020 |
Why?
|
Specialization | 1 | 2009 | 120 | 0.020 |
Why?
|
Apelin Receptors | 1 | 2007 | 4 | 0.020 |
Why?
|
Apelin | 1 | 2007 | 9 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2012 | 539 | 0.020 |
Why?
|
raf Kinases | 1 | 2007 | 12 | 0.020 |
Why?
|
Velopharyngeal Insufficiency | 1 | 2006 | 10 | 0.020 |
Why?
|
RNA | 1 | 2013 | 833 | 0.020 |
Why?
|
3,4-Dihydroxyphenylacetic Acid | 1 | 2006 | 17 | 0.020 |
Why?
|
Pulmonary Wedge Pressure | 1 | 2007 | 65 | 0.020 |
Why?
|
Catechols | 1 | 2006 | 16 | 0.020 |
Why?
|
Levodopa | 1 | 2006 | 23 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 160 | 0.020 |
Why?
|
Nerve Degeneration | 1 | 2006 | 44 | 0.020 |
Why?
|
Tyrosine 3-Monooxygenase | 1 | 2006 | 70 | 0.020 |
Why?
|
Decision Making | 1 | 2013 | 809 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2009 | 261 | 0.020 |
Why?
|
Parkinsonian Disorders | 1 | 2006 | 29 | 0.020 |
Why?
|
Drug Industry | 1 | 2007 | 104 | 0.020 |
Why?
|
Patient Compliance | 1 | 2010 | 537 | 0.020 |
Why?
|
Solubility | 1 | 2006 | 235 | 0.020 |
Why?
|
Cell Death | 1 | 2007 | 339 | 0.020 |
Why?
|
Tretinoin | 1 | 2006 | 116 | 0.020 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2007 | 200 | 0.020 |
Why?
|
Medical Records | 1 | 2006 | 163 | 0.020 |
Why?
|
Neuroblastoma | 1 | 2006 | 135 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 369 | 0.020 |
Why?
|
Hypertension | 1 | 2014 | 1203 | 0.020 |
Why?
|
Receptor, TIE-2 | 1 | 2004 | 12 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2007 | 420 | 0.020 |
Why?
|
Excitatory Amino Acid Transporter 2 | 1 | 2004 | 13 | 0.020 |
Why?
|
Cardiomegaly | 1 | 2006 | 168 | 0.020 |
Why?
|
Skin | 1 | 2009 | 657 | 0.020 |
Why?
|
Synucleins | 1 | 2004 | 5 | 0.020 |
Why?
|
Immunotherapy | 1 | 2009 | 493 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2006 | 300 | 0.020 |
Why?
|
Valine | 1 | 2004 | 77 | 0.020 |
Why?
|
Cell Count | 1 | 2004 | 315 | 0.020 |
Why?
|
Cell Survival | 1 | 2007 | 1047 | 0.020 |
Why?
|
Receptors, GABA-A | 1 | 2004 | 89 | 0.020 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2004 | 139 | 0.020 |
Why?
|
Methionine | 1 | 2004 | 145 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 653 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2008 | 597 | 0.010 |
Why?
|
Protein Conformation | 1 | 2006 | 848 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 2006 | 940 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2010 | 628 | 0.010 |
Why?
|
Molecular Chaperones | 1 | 2004 | 174 | 0.010 |
Why?
|
Communication | 1 | 2009 | 761 | 0.010 |
Why?
|
Health Services Needs and Demand | 1 | 2005 | 254 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2010 | 940 | 0.010 |
Why?
|
Lung Diseases, Parasitic | 1 | 2002 | 2 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2007 | 2478 | 0.010 |
Why?
|
HIV-1 | 1 | 2007 | 776 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2004 | 477 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2006 | 2025 | 0.010 |
Why?
|
Protein Binding | 1 | 2004 | 1975 | 0.010 |
Why?
|